Please assess the completion status of the following clinical trial:

Trial Title: A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary PCI for acute STEMI between 2-24 hours after onset of chest pain.~* ST-segment elevation \>=2mm in \>=3 adjacent leads.~* Presence of severe hypokinesia and/or akinesia in \>=2 adjacent segments on echocardiogram at 48-72 hrs after primary PCI.~* Age between 20 and 75 years.~Exclusion Criteria:~* Pregnant or lactating.~* Prior history of myocardial infarction before index event.~* Decompensated congestive heart failure.~* Pre-existent LV dysfunction (EF \<45% prior to admission)~* Cardiomyopathy.~* Previous cardiac surgery.~* Congenital heart disorder.~* Serum creatinine \>200 Mmol/L.~* Presence of permanent pacemaker or implantable defibrillator.~* Contraindication to bone marrow aspiration.~* History of malignancy within 5 years except curatively treated basal cell carcinoma, squamous cell carcinoma and/or cervical carcinoma.~* Sustained or inducible VT \>48 hours post primary PCI.~* Three vessel coronary artery disease necessitating intervention within 4 months.~* Immune compromise including chronic human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.~* Presence of chronic systemic inflammatory disorders.~* Previous autologous or allogeneic bone marrow or peripheral stem cell transplant or prior solid organ transplantation.~* Low hemoglobin, white blood cell, absolute neutrophil and/or platelet count.~* Any condition associated with a life expectancy of less than 6 months.~* Participation in unrelated research involving investigational pharmacological agent(s) 30 days before planned dosing.~* Current alcohol or drug abuse.~* Inability to provide written informed consent.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Enriched CD133+, bone marrow-derived, autologous progenitor cells for this trial will be infused in the coronary arteries
- 2 (Type: PLACEBO_COMPARATOR): Control group patients will receive 3 injections of 0.3 mL each of buffered normal saline (the vehicle used for cell suspension) into comparable vessels. Subjects will have an identical intra-coronary injection procedure to those randomized to autologous CD133+ progenitor cell injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).